In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Revlon management

This article was originally published in The Rose Sheet

Executive Summary

Coca-Cola exec David Kennedy joins firm as exec VP and president of Revlon International, company announces. He will be responsible for general management of Revlon's international business, reporting directly to CEO Jack Stahl. Kennedy worked for Coca-Cola for more than 20 years, most recently as managing director of Coca-Cola Amatil Limited, which operates in seven countries including Australia, New Zealand, South Korea and Indonesia. Exec is credited with helping the Amatil division achieve 11% annual average compound volume growth and improved profits, company says. Revlon's business outside the U.S. and Canada accounted for 32% of net sales in 2001. Stahl joined Revlon from Coca-Cola in February (1"The Rose Sheet" Feb. 5, 2002, p. 6)...

You may also be interested in...

Revlon Brand Management Responsibilities To Be Assigned By New CEO Stahl

One of the first tasks facing Revlon's newly-appointed President and CEO Jack Stahl will be delegating management duties for the company's key Revlon brand following the resignation of Revlon Brand Equity Group Exec VP and General Manger Cheryl Vitali

US Senate Passes First Monograph Reform Bill After House Passed Three

Senate's Over-the-Counter Monograph Safety, Innovation, and Reform Act goes next for consideration by House, which has had a bill by the same title on its floor for a vote since it was passed by Energy and Commerce Committee in late June.

Homeopathic Firm's Teething Remedy Touches FDA Enforcement Nerve

FDA warns OHM Pharma for promoting topical formula containing homeopathic ingredients as teething product for infants. The firm also warned about drug and supplements GMP violations and was an easy target for FDA following release of draft guidance outlining its enforcement priorities.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts